Osteonecrosis of the jaw under palbociclib: A case series description

• Published in: Journal of oncology pharmacy practice 2023-12, Vol.29 (8), p.1990-1997
• Main Authors: Yosofi, Chabnam, Cairon-Lejeune, Sophie, Lefeuvre-Plesse, Claudia, Polard, Elisabeth, Briet, Marie, Kammerer-Jacquet, Solène-Florence, Triquet, Louise, Scailteux, Lucie-Marie
• Format: Article
• Language: English
• Subjects: Cyclin-dependent kinase; Cyclin-dependent kinase 4; Cyclin-dependent kinases; Dentures; Diagnosis; Enzyme inhibitors; Jaw; Kinases; Life Sciences; Mucositis; Necrosis; Neutropenia; Osteonecrosis; Patients; Pharmacovigilance; Risk factors
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/10781552231165434

Introduction Cases of osteonecrosis of the jaw have been reported by dental surgeons to the pharmacovigilance center in Rennes, France, occurring among patients treated with palbociclib, a cyclin-dependent kinase 4/6 inhibitor. Although this event was not expected with the drug, a safety signal was raised. Describing a local case series, the aim of our study was to identify specific patterns that might suggest a triggering role for these drugs, and to discuss pathophysiological hypotheses. Materials and methods A retrospective case series of patients exposed to cyclin-dependent kinase 4/6 inhibitors between 2016 and 2020 with a diagnosis of osteonecrosis of the jaw at the Rennes Dental Care Center was analyzed. The descriptive analysis was conducted on patient demographics, breast cancer characteristics, osteonecrosis of the jaw, biological data, and exposure to cyclin-dependent kinase 4/6 inhibitors. Results We identified eight cases, most of them at stages 0–1 (62.5%). Four patients were still exposed to palbociclib at the time of diagnosis and four had discontinued the treatment before the diagnosis. Chronological imputability could not be excluded given the drug’s half-life and the variable intervals of dental monitoring from one patient to another. All patients had at least one dental osteonecrosis risk factor (including dental extraction, dentures, and denosumab exposure at the time of diagnosis). Neutropenia and mucositis were not systematically reported at the time of diagnosis. The anatomopathological characteristics were nonspecific. Conclusion We did not identify a specific pattern that could suggest a triggering role of palbociclib in the development of ONJ.